Phendimetrazine Tartrate has 5 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Monoamine Oxidase Inhibitors (Maois), Other Anticholinergic Agents, Adrenergic Blockers. Patients taking Phendimetrazine Tartrate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 5
- Contraindicated
- 1
- Major
- 1
- Moderate
- 3
Contraindicated (1)
- Phendimetrazine Tartrate + Monoamine Oxidase Inhibitors (Maois)— Contraindicated during or within 14 days of MAOi use due to risk of hypertensive crisis.
Major (1)
- Phendimetrazine Tartrate + Other Anticholinergic Agents— Combined use may have the potential for serious cardiac problems. Efficacy has not been studied.
Moderate (3)
- Phendimetrazine Tartrate + Adrenergic Blockers— Phendimetrazine tartrate may decrease the hypotensive effect of adrenergic neuron blocking drugs.
- Phendimetrazine Tartrate + Alcohol— Concomitant use may result in an adverse drug reaction.
- Phendimetrazine Tartrate + Insulin Human— Phendimetrazine tartrate may alter insulin requirements.